Tumor Stroma-Penetrating Oligomicelles Containing Combination Payload for Reversal of Drug Resistance and Immune Modulation in Kidney Cancer

Abstract

Renal Cell Carcinoma (RCC) is the most common form of kidney cancer and remains one of the 10 leading causes of cancer death in the US. In 2017, 63,990 people are estimated to be diagnosed with RCC, and about 14,400 people are estimated to die from this disease. In addition, kidney cancer affects military personnel and their dependents and Veterans. The insult to the body during active military duty may cause kidney cancer but may not appear until later in life therefore affecting Veterans more frequently than their US civilian counterparts. The economic burden of RCC is also significant. Approximately $3.8 billion (B) is spent annually on its treatment with the projected costs reaching $5.3B for the year 2020. RCC is difficult to treat as the cancer is largely resistant to many current therapies. RCC is also generally diagnosed at the late stages, when the tumors have grown larger. Thus, newer (combination) targeted therapies, including better ways of drug delivery and imaging, is urgently needed to effectively combat this malignant disease. In this regard, our strategy is to design and develop a cancer multicomponent targeting nanotechnology-based library approach. The tumor multicomponent targeting nanoformulations will be co-loaded with unique drug combinations that can work in synergy, with multiple modes of action including rejuvenating the body s own immune system to effectively fight the cancer. Our preliminary data based on this concept is very promising and the proposed project will involve further critical evaluation of the nanoformulations to validate our initial findings that can result in improved drug delivery efficiency, efficacy, and safety in animal models that can be applied for future clinical translation. This project is thus expected to result in new directions for kidney cancer therapy and diagnosis that would ultimately benefit Veterans and civilians with RCC.

Document Details

Document Type
DoD Grant Award
Publication Date
Oct 29, 2018
Source ID
W81XWH1810471

Entities

People

  • Arun K Iyer

Organizations

  • United States Army
  • Wayne State University

Tags

Readers

  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech